496.82

0.38% -1.1505

United Therapeutics Corp (UTHR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt UTHR? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$497.97

Offen:

$502.75

24-Stunden-Volumen:

74,843

Relative Volume:

0.15

Marktkapitalisierung:

$21.33B

Einnahmen:

$3.17B

Nettoeinkommen (Verlust:

$1.29B

KGV:

18.34

EPS:

27.0947

Netto-Cashflow:

$1.01B

1W Leistung:

+0.83%

1M Leistung:

-7.93%

6M Leistung:

-6.25%

1J Leistung:

+22.85%

1-Tages-Spanne:

$492.90

$502.75

1-Wochen-Bereich:

$477.06

$505.00

52-Wochen-Spanne:

$395.00

$609.35

United Therapeutics Corp Stock (UTHR) Company Profile

Firmenname

United Therapeutics Corp

Sektor

Healthcare (1087)

Branche

Drug Manufacturers - Specialty & Generic (87)

Telefon

(301) 608-9292

Adresse

1000 SPRING ST, SILVER SPRING, MD

Mitarbeiter

1,400

Twitter

Nächster Verdiensttermin

2026-08-05

Neueste SEC-Einreichungen

UTHR's Discussions on Twitter

Compare UTHR vs TAK, TEVA, HLN, ZTS

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
UTHR United Therapeutics Corp	497.22	21.36B	3.17B	1.29B	1.01B	27.09
TAK Takeda Pharmaceutical Co Adr	18.27	58.50B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.88	42.84B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.17	40.68B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	73.50	30.40B	9.51B	2.64B	2.14B	6.0361

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-10	Eingeleitet	Raymond James	Outperform
2025-10-20	Eingeleitet	Wells Fargo	Underweight
2025-09-26	Eingeleitet	RBC Capital Mkts	Outperform
2025-06-02	Eingeleitet	Cantor Fitzgerald	Overweight
2025-04-25	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-04-21	Hochstufung	BofA Securities	Underperform → Neutral
2024-07-11	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2024-02-12	Hochstufung	Goldman	Sell → Neutral
2024-02-05	Eingeleitet	Leerink Partners	Outperform
2023-12-08	Eingeleitet	Wells Fargo	Overweight
2022-12-06	Eingeleitet	UBS	Buy
2022-12-05	Eingeleitet	Goldman	Sell
2022-10-11	Eingeleitet	Morgan Stanley	Overweight
2022-09-20	Bestätigt	BofA Securities	Underperform
2022-09-19	Fortgesetzt	Wedbush	Outperform
2022-02-11	Eingeleitet	BTIG Research	Neutral
2021-07-14	Hochstufung	Argus	Hold → Buy
2021-04-26	Fortgesetzt	Credit Suisse	Outperform
2021-02-01	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-09-14	Fortgesetzt	JP Morgan	Overweight
2020-06-25	Bestätigt	H.C. Wainwright	Neutral
2020-03-10	Hochstufung	Jefferies	Hold → Buy
2020-02-27	Hochstufung	Cowen	Market Perform → Outperform
2020-01-31	Hochstufung	JP Morgan	Neutral → Overweight
2019-12-03	Eingeleitet	BofA/Merrill	Underperform
2019-08-01	Hochstufung	Jefferies	Underperform → Hold
2019-08-01	Hochstufung	Ladenburg Thalmann	Neutral → Buy
2019-07-01	Hochstufung	Credit Suisse	Neutral → Outperform
2019-05-17	Hochstufung	UBS	Sell → Neutral
2019-05-09	Hochstufung	Credit Suisse	Underperform → Neutral
2018-10-12	Hochstufung	Standpoint Research	Hold → Buy
2018-08-08	Herabstufung	Credit Suisse	Neutral → Underperform
2018-04-03	Hochstufung	Credit Suisse	Underperform → Neutral
2018-02-22	Bestätigt	Barclays	Underweight
2018-01-18	Fortgesetzt	Credit Suisse	Underperform
2017-12-27	Bestätigt	Wedbush	Outperform
2017-04-27	Bestätigt	Wedbush	Outperform
2017-03-30	Eingeleitet	UBS	Sell
2017-03-16	Eingeleitet	Credit Suisse	Underperform

Alle ansehen

United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten

Sep 08, 2026

United Therapeutics Launches $477.6M Accelerated Share Buyback - Minichart

Sep 08, 2026

United Therapeutics Launches $477.6 Million Accelerated Share Repurchase With Citi - TradingView

Sep 08, 2026

United Therapeutics (UTHR) moves to return $4B to shareholders with new buyback - Stock Titan

Sep 08, 2026

United Therapeutics (UTHR) CEO sells 9,500 shares under preset trading plan - Stock Titan

Sep 08, 2026

United Therapeutics Corporation at Wells Fargo Healthcare Conference Transcript - GuruFocus

Sep 08, 2026

United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization - marketscreener.com

Sep 08, 2026

Sep 07, 2026

United Therapeutics Corporation (UTHR) Stock Analysis: Insights on a 36.24% Potential Upside - DirectorsTalk Interviews

Sep 07, 2026

Sep 04, 2026

United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan

Sep 04, 2026

MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits

Sep 04, 2026

United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Sep 04, 2026

Sep 03, 2026

Anheuser-Busch plant in Merrimack sold to United Therapeutics for $47.5M - UnionLeader.com

Sep 03, 2026

United Therapeutics EVP Paul A. Mahon Executes Stock Option Exercise and Sells Shares Under 10b5-1 Plan - kalkinemedia.com

Sep 03, 2026

United Therapeutics (UTHR) counsel sells 8,300 shares under preset plan - Stock Titan

Sep 03, 2026

United Therapeutics (UTHR) CEO offloads 9,500 shares in planned trade - Stock Titan

Sep 03, 2026

United Therapeutics (NASDAQ:UTHR) Offers Growth At A Fair Price - Kalkine Media

Sep 03, 2026

United Therapeutics (NASDAQ:UTHR) Fits the Growth-at-a-Reasonable-Price Model - ChartMill

Sep 03, 2026

Sep 02, 2026

Merrimack’s Anheuser-Busch property sold for $47m - The Cabinet Press

Sep 02, 2026